Henry Fuchs J.'s most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 12,098 Common Stock done at an average price of $84.9 . Disclosure was reported to the exchange on Sept. 13, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.90 per share. | 13 Sep 2024 | 12,098 | 185,074 (0%) | 0% | 84.9 | 1,027,120 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 68.65 per share. | 13 Sep 2024 | 300 | 197,172 (0%) | 0% | 68.6 | 20,594 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 40,860 | 40,860 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.87 per share. | 15 Mar 2024 | 33,485 | 196,872 (0%) | 0% | 83.9 | 2,808,387 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 18,240 | 230,357 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Sale of securities on an exchange or to another person at price $ 85.18 per share. | 05 Mar 2024 | 35,341 | 212,117 (0%) | 0% | 85.2 | 3,010,396 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry Fuchs J. | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 30,640 | 224,894 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Fuchs Henry J. | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 13,326 | 238,220 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Fuchs Henry J. | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 9,238 | 247,458 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | J. Henry Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 17,750 | 194,254 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | J. Henry Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 66.88 per share. | 01 Dec 2023 | 317 | 176,504 (0%) | 0% | 66.9 | 21,200 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Sale of securities on an exchange or to another person at price $ 90.43 per share. | 10 Aug 2023 | 12,000 | 176,187 (0%) | 0% | 90.4 | 1,085,111 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 38,450 | 38,450 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.41 per share. | 15 Mar 2023 | 36,000 | 188,187 (0%) | 0% | 93.4 | 3,362,760 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 16,840 | 228,986 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.74 per share. | 15 Mar 2023 | 4,799 | 224,187 (0%) | 0% | 87.7 | 421,064 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 36,440 | 180,534 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 18,220 | 198,754 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 13,392 | 212,146 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 7,520 | 7,520 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2023 | 4,444 | 10,465 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 31 Dec 2022 | 341 | 144,094 (0%) | 0% | 62.4 | 21,281 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 38,790 | 158,113 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 35,830 | 35,830 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.27 per share. | 15 Mar 2022 | 12,101 | 146,012 (0%) | 0% | 78.3 | 947,145 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.72 per share. | 15 Mar 2022 | 2,259 | 143,753 (0%) | 0% | 80.7 | 182,346 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 12,840 | 119,323 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Sale of securities on an exchange or to another person at price $ 105.80 per share. | 11 Feb 2022 | 8,700 | 6,231 (0%) | 0% | 105.8 | 920,428 | Common Stock |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 6,000 | 0 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.54 per share. | 11 Feb 2022 | 6,000 | 12,021 (0%) | 0% | 20.5 | 123,240 | Common Stock |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 5,000 | 0 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.54 per share. | 11 Feb 2022 | 5,000 | 17,021 (0%) | 0% | 20.5 | 102,700 | Common Stock |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Sale of securities on an exchange or to another person at price $ 104.76 per share. | 11 Feb 2022 | 2,090 | 14,931 (0%) | 0% | 104.8 | 218,958 | Common Stock |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Sale of securities on an exchange or to another person at price $ 106.34 per share. | 11 Feb 2022 | 210 | 6,021 (0%) | 0% | 106.3 | 22,332 | Common Stock |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 3,688 | 3,688 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Henry J. Fuchs | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 2,546 | 6,021 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.52 per share. | 22 Mar 2021 | 2,454 | 106,142 (0%) | 0% | 78.5 | 192,688 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 37,710 | 37,710 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 15,320 | 118,315 (0%) | 0% | 0 | Common Stock | |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.39 per share. | 15 Mar 2021 | 7,460 | 110,855 (0%) | 0% | 78.4 | 584,789 | Common Stock |
| Biomarin pharma Inc - Registered Shares | Henry J. Fuchs | President, Worldwide R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.21 per share. | 15 Mar 2021 | 2,259 | 108,596 (0%) | 0% | 77.2 | 174,417 | Common Stock |